Frequency Therapeutics (FREQ) Stock Price, News & Analysis

Company Overview

Frequency Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics to activate a person's innate regenerative potential to restore function. Its Progenitor Cell Activation approach uses small molecules to activate progenitor cells within the body to create functional tissue. The company's lead product candidate is FX-322, which is in Phase IIb clinical trial to treat the underlying cause of sensorineural hearing loss. It is also developing medicines for patients across a range of degenerative conditions, including multiple sclerosis, and diseases of the muscle, gastrointestinal tract, skin, and bone. The company has a license and collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322, as well as collaboration and licensing agreements with Massachusetts Eye and Ear, the Massachusetts Institute of Technology, and The Scripps Research Institute. Frequency Therapeutics, Inc. was incorporated in 2014 and is headquartered in Lexington, Massachusetts.

Key Stats

• Today's Range: $0.28 to $0.32
• 50-Day Range: $0.22 to $14.98
• 52-Week Range: $0.18 to $16.00
• Volume: 309,164 shs
• Average Volume: 822,537 shs
• Market Capitalization: $10.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FREQ Stock Analysis - Frequently Asked Questions

How were Frequency Therapeutics' earnings last quarter?

Frequency Therapeutics, Inc. (NASDAQ:FREQ) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.73) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.16.

When did Frequency Therapeutics IPO?

Frequency Therapeutics (FREQ) raised $102 million in an initial public offering (IPO) on Thursday, October 3rd 2019. The company issued 6,700,000 shares at $14.50-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Mizuho Securities was co-manager.

What other stocks do shareholders of Frequency Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Frequency Therapeutics investors own include Tesla (TSLA), ImmunoGen (IMGN), Advanced Micro Devices (AMD), AMC Entertainment (AMC), Ovintiv (OVV), Plug Power (PLUG) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 10/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FREQ
• CUSIP: N/A
• CIK: 1703647
• Web: www.frequencytx.com
• Phone: 781-315-4600
• Fax: N/A
• Employees: 46
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-81,580,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -107.67%
• Return on Assets: -61.40%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.81
• Quick Ratio: 5.81

Sales & Book Value

• Annual Sales: $14.07 million
• Price / Sales: 0.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.96 per share
• Price / Book: 0.15

Miscellaneous

• Outstanding Shares: 36,520,000
• Free Float: 30,385,000
• Market Cap: $10.94 million
• Optionable: Not Optionable
• Beta: 0.84